Targeting erythropoietin for chronic neurodegenerative diseases

Bibliography

• Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem 1977;252:5558-64
   PubMed Web of Science ®Google Scholar
• Maiese K, Chong ZZ, Shang YC, et al. Erythropoietin: new directions for the nervous system. Int J Mol Sci 2012;13:11102-29
   PubMed Web of Science ®Google Scholar
• Fisher JW. Erythropoietin: physiology and pharmacology update. Exp Biol Med (Maywood) 2003;228:1-14
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Kang JQ, Maiese K. Hematopoietic factor erythropoietin fosters neuroprotection through novel signal transduction cascades. J Cereb Blood Flow Metab 2002;22:503-14
   PubMedGoogle Scholar
• Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91:3974-8
   PubMed Web of Science ®Google Scholar
• Ribatti D, Presta M, Vacca A, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627-36
   PubMed Web of Science ®Google Scholar
• Littlewood TJ. Erythropoietin for the treatment of anemia associated with hematological malignancy. Hematol Oncol 2001;19:19-30
   PubMed Web of Science ®Google Scholar
• Masuda S, Okano M, Yamagishi K, et al. A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 1994;269:19488-93
   PubMed Web of Science ®Google Scholar
• Masuda S, Nagao M, Takahata K, et al. Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 1993;268:11208-16
   PubMed Web of Science ®Google Scholar
• Digicaylioglu M, Bichet S, Marti HH, et al. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. Proc Natl Acad Sci USA 1995;92:3717-20
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Kang JQ, Maiese K. Apaf-1, Bcl-xL, cytochrome c, and caspase-9 form the critical elements for cerebral vascular protection by erythropoietin. J Cereb Blood Flow Metab 2003;23:320-30
   PubMed Web of Science ®Google Scholar
• Morishita E, Masuda S, Nagao M, et al. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997;76:105-16
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Kang JQ, Maiese K. Erythropoietin fosters both intrinsic and extrinsic neuronal protection through modulation of microglia, Akt1, Bad, and caspase-mediated pathways. Br J Pharmacol 2003;138:1107-18
   PubMed Web of Science ®Google Scholar
• Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, monkey and murine brain. Eur J Neurosci 1996;8:666-76
   PubMed Web of Science ®Google Scholar
• Juul SE, Yachnis AT, Rojiani AM, et al. Immunohistochemical localization of erythropoietin and its receptor in the developing human brain. Pediatr Dev Pathol 1999;2:148-58
   PubMed Web of Science ®Google Scholar
• Marti HH, Gassmann M, Wenger RH, et al. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int 1997;51:416-18
   PubMed Web of Science ®Google Scholar
• Velly L, Pellegrini L, Guillet B, et al. Erythropoietin 2nd cerebral protection after acute injuries: a double-edged sword? Pharmacol Ther 2010;128:445-59
   PubMed Web of Science ®Google Scholar
• Genc S, Koroglu TF, Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 2004;22:105-19
   PubMed Web of Science ®Google Scholar
• Marti HH. Erythropoietin and the hypoxic brain. J Exp Biol 2004;207:3233-42
   PubMed Web of Science ®Google Scholar
• Lykissas MG, Korompilias AV, Vekris MD, et al. The role of erythropoietin in central and peripheral nerve injury. Clin Neurol Neurosurg 2007;109:639-44
   PubMedGoogle Scholar
• Maiese K, Li F, Chong ZZ. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 2004;25:577-83
   PubMed Web of Science ®Google Scholar
• Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005;293:90-5
   PubMed Web of Science ®Google Scholar
• Kato S, Aoyama M, Kakita H, et al. Endogenous erythropoietin from astrocyte protects the oligodendrocyte precursor cell against hypoxic and reoxygenation injury. J Neurosci Res 2011;89:1566-74
   PubMed Web of Science ®Google Scholar
• Yoo JY, Won YJ, Lee JH, et al. Neuroprotective effects of erythropoietin posttreatment against kainate-induced excitotoxicity in mixed spinal cultures. J Neurosci Res 2009;87:150-63
   PubMedGoogle Scholar
• Chong ZZ, Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol 2007;150:839-50
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Kang JQ, Maiese K. Erythropoietin is a novel vascular protectant through activation of Akt1 and mitochondrial modulation of cysteine proteases. Circulation 2002;106:2973-9
   PubMed Web of Science ®Google Scholar
• Wenker SD, Chamorro ME, Vota DM, et al. Differential antiapoptotic effect of erythropoietin on undifferentiated and retinoic acid-differentiated SH-SY5Y cells. J Cell Biochem 2010;110:151-61
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Shang YC, Wang S, et al. PRAS40 Is an Integral Regulatory Component of Erythropoietin mTOR Signaling and Cytoprotection. PLoS One 2012;7:e45456
   PubMed Web of Science ®Google Scholar
• Chen J, Connor KM, Aderman CM, et al. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest 2008;118:526-33
   PubMed Web of Science ®Google Scholar
• Liu R, Suzuki A, Guo Z, et al. Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro. J Neurochem 2006;96:1101-10
   PubMed Web of Science ®Google Scholar
• Shang YC, Chong ZZ, Wang S, et al. Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia. Curr Neurovasc Res 2011;8:270-85
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Li F, Maiese K. The pro-survival pathways of mTOR and protein kinase B target glycogen synthase kinase-3beta and nuclear factor-kappaB to foster endogenous microglial cell protection. Int J Mol Med 2007;19:263-72
   PubMedGoogle Scholar
• Chong ZZ, Shang YC, Maiese K. Vascular injury during elevated glucose can be mitigated by erythropoietin and Wnt signaling. Curr Neurovasc Res 2007;4:194-204
   PubMed Web of Science ®Google Scholar
• Hou J, Wang S, Shang YC, et al. Erythropoietin employs cell longevity pathways of SIRT1 to foster endothelial vascular integrity during oxidant stress. Curr Neurovasc Res 2011;8:220-35
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Hou J, Shang YC, et al. EPO relies upon novel signaling of Wnt1 that requires Akt1, FoxO3a, GSK-3beta, and beta-catenin to foster vascular integrity during experimental diabetes. Curr Neurovasc Res 2011;8:103-20
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Lin SH, Kang JQ, et al. Erythropoietin prevents early and late neuronal demise through modulation of Akt1 and induction of caspase 1, 3, and 8. J Neurosci Res 2003;71:659-69
   PubMed Web of Science ®Google Scholar
• Zhong Y, Yao H, Deng L, et al. Promotion of neurite outgrowth and protective effect of erythropoietin on the retinal neurons of rats. Graefes Arch Clin Exp Ophthalmol 2007;245:1859-67
   PubMed Web of Science ®Google Scholar
• Park KH, Choi NY, Koh SH, et al. L-DOPA neurotoxicity is prevented by neuroprotective effects of erythropoietin. Neurotoxicology 2011;32:879-87
   PubMed Web of Science ®Google Scholar
• Wu Y, Shang Y, Sun S, et al. Antioxidant effect of erythropoietin on 1-methyl-4-phenylpyridinium-induced neurotoxicity in PC12 cells. Eur J Pharmacol 2007;564:47-56
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Li F, Maiese K. Erythropoietin requires NF-kappaB and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Curr Neurovasc Res 2005;2:387-99
   PubMed Web of Science ®Google Scholar
• Shang YC, Chong ZZ, Wang S, et al. Prevention of beta-amyloid degeneration of microglia by erythropoietin depends on Wnt1, the PI 3-K/mTOR pathway, Bad, and Bcl-xL. Aging (Albany NY) 2012;4:187-201
   PubMedGoogle Scholar
• Ma R, Xiong N, Huang C, et al. Erythropoietin protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3K/Akt signaling pathway. Neuropharmacology 2009;56:1027-34
   PubMed Web of Science ®Google Scholar
• Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75
   PubMed Web of Science ®Google Scholar
• Verdier F, Walrafen P, Hubert N, et al. Proteasomes regulate the duration of erythropoietin receptor activation by controlling down-regulation of cell surface receptors. J Biol Chem 2000;275:18375-81
   PubMed Web of Science ®Google Scholar
• Shingo T, Sorokan ST, Shimazaki T, et al. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci 2001;21:9733-43
   PubMed Web of Science ®Google Scholar
• Maiese K, Li F, Chong ZZ. Erythropoietin in the brain: can the promise to protect be fulfilled? Trends Pharmacol Sci 2004;25:577-83
   PubMed Web of Science ®Google Scholar
• Chen ZY, Asavaritikrai P, Prchal JT, et al. Endogenous erythropoietin signaling is required for normal neural progenitor cell proliferation. J Biol Chem 2007;282:25875-83
   PubMed Web of Science ®Google Scholar
• Gonzalez FF, McQuillen P, Mu D, et al. Erythropoietin enhances long-term neuroprotection and neurogenesis in neonatal stroke. Dev Neurosci 2007;29:321-30
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang Z, Wang Y, et al. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 2004;35:1732-7
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang ZG, Zhang RL, et al. Neurogenin 1 mediates erythropoietin enhanced differentiation of adult neural progenitor cells. J Cereb Blood Flow Metab 2006;26:556-64
   PubMedGoogle Scholar
• Byts N, Siren AL. Erythropoietin: a multimodal neuroprotective agent. Exp Transl Stroke Med 2009;1:4
   PubMedGoogle Scholar
• Mulcahy L. The erythropoietin receptor. Semin Oncol 2001;28:19-23
   PubMed Web of Science ®Google Scholar
• Witthuhn BA, Quelle FW, Silvennoinen O, et al. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell 1993;74:227-36
   PubMed Web of Science ®Google Scholar
• Zhao Y, Wagner F, Frank SJ, et al. The amino-terminal portion of the JAK2 protein kinase is necessary for binding and phosphorylation of the granulocyte-macrophage colony- stimulating factor receptor beta c chain. J Biol Chem 1995;270:13814-18
   PubMedGoogle Scholar
• Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641-7
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Li F, Maiese K. Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol Histopathol 2005;20:299-315
   PubMed Web of Science ®Google Scholar
• Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science 1998;279:710-14
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Shang YC, Wang S, et al. A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR. Fut Neurol 2012;7:733-48
   PubMedGoogle Scholar
• Nguyen MH, Ho JM, Beattie BK, et al. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway. J Biol Chem 2001;276:32704-13
   PubMedGoogle Scholar
• Das M, Scappini E, Martin NP, et al. Regulation of neuron survival through an intersectin-phosphoinositide 3'-kinase C2beta-AKT pathway. Mol Cell Biol 2007;27:7906-17
   PubMedGoogle Scholar
• Yu F, Sugawara T, Maier CM, et al. Akt/Bad signaling and motor neuron survival after spinal cord injury. Neurobiol Dis 2005;20:491-9
   PubMed Web of Science ®Google Scholar
• Matsuzaki H, Tamatani M, Mitsuda N, et al. Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J Neurochem 1999;73:2037-46
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Li F, Maiese K. Group I metabotropic receptor neuroprotection requires Akt and its substrates that govern FOXO3a, Bim, and beta-catenin during oxidative stress. Curr Neurovasc Res 2006;3:107-17
   PubMedGoogle Scholar
• Chong ZZ, Kang JQ, Maiese K. AKT1 drives endothelial cell membrane asymmetry and microglial activation through Bcl-xL and caspase 1, 3, and 9. Exp Cell Res 2004;296:196-207
   PubMed Web of Science ®Google Scholar
• Kang JQ, Chong ZZ, Maiese K. Critical role for Akt1 in the modulation of apoptotic phosphatidylserine exposure and microglial activation. Mol Pharmacol 2003;64:557-69
   PubMedGoogle Scholar
• Matis GK, Birbilis TA. Erythropoietin in spinal cord injury. Eur Spine J 2009;18:314-23
   PubMed Web of Science ®Google Scholar
• Shen J, Wu Y, Xu JY, et al. ERK- and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest Ophthalmol Vis Sci 2010;51:35-46
   PubMed Web of Science ®Google Scholar
• Mahmud DL, G-Amlak M, Deb DK, et al. Phosphorylation of forkhead transcription factors by erythropoietin and stem cell factor prevents acetylation and their interaction with coactivator p300 in erythroid progenitor cells. Oncogene 2002;21:1556-62
   PubMedGoogle Scholar
• Maiese K, Chong ZZ, Li F, et al. Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies. Prog Neurobiol 2008;85:194-213
   PubMed Web of Science ®Google Scholar
• Brunet A, Bonni A, Zigmond MJ, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999;96:857-68
   PubMed Web of Science ®Google Scholar
• Hou J, Chong ZZ, Shang YC, et al. FOXO3a governs early and late apoptotic endothelial programs during elevated glucose through mitochondrial and caspase signaling. Mol Cell Endocrinol 2010;321:194-206
   PubMedGoogle Scholar
• Shang YC, Chong ZZ, Hou J, et al. FoxO3a governs early microglial proliferation and employs mitochondrial depolarization with caspase 3, 8, and 9 cleavage during oxidant induced apoptosis. Curr Neurovasc Res 2009;6:223-38
   PubMedGoogle Scholar
• Shang YC, Chong ZZ, Hou J, et al. The forkhead transcription factor FOXO3a controls microglial inflammatory activation and eventual apoptotic injury through caspase 3. Curr Neurovasc Res 2009;6:20-31
   PubMedGoogle Scholar
• Shang YC, Chong ZZ, Hou J, et al. Wnt1, FoxO3a, and NF-kappaB oversee microglial integrity and activation during oxidant stress. Cell Signal 2010;22:1317-29
   PubMedGoogle Scholar
• Kim KH, Oudit GY, Backx PH. Erythropoietin protects against doxorubicin-induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther 2008;324:160-9
   PubMedGoogle Scholar
• Shang Y, Wu Y, Yao S, et al. Protective effect of erythropoietin against ketamine-induced apoptosis in cultured rat cortical neurons: involvement of PI3K/Akt and GSK-3 beta pathway. Apoptosis 2007;12:2187-95
   PubMed Web of Science ®Google Scholar
• Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Shang YC, Wang S, et al. Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin. Prog Neurobiol 2012;99:128-48
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Shang YC, Zhang L, et al. Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid Med Cell Longev 2010;3:374-91
   PubMed Web of Science ®Google Scholar
• Chen L, Xu B, Liu L, et al. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Lab Invest 2010;90:762-73
   PubMed Web of Science ®Google Scholar
• Wang L, Harris TE, Roth RA, et al. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 2007;282:20036-44
   PubMed Web of Science ®Google Scholar
• Nascimento EB, Snel M, Guigas B, et al. Phosphorylation of PRAS40 on Thr246 by PKB/AKT facilitates efficient phosphorylation of Ser183 by mTORC1. Cell Signal 2010;22:961-7
   PubMed Web of Science ®Google Scholar
• Li F, Chong ZZ, Maiese K. Microglial integrity is maintained by erythropoietin through integration of Akt and its substrates of glycogen synthase kinase-3beta, beta-catenin, and nuclear factor-kappaB. Curr Neurovasc Res 2006;3:187-201
   PubMed Web of Science ®Google Scholar
• Kyriakis JM. Life-or-death decisions. Nature 2001;414:265-6
   PubMedGoogle Scholar
• Zou T, Rao JN, Guo X, et al. NF-kappaB-mediated IAP expression induces resistance of intestinal epithelial cells to apoptosis after polyamine depletion. Am J Physiol Cell Physiol 2004;286:C1009-18
   Web of Science ®Google Scholar
• Reed JC. Apoptosis-regulating proteins as targets for drug discovery. Trends Mol Med 2001;7:314-19
   PubMed Web of Science ®Google Scholar
• De Smaele E, Zazzeroni F, Papa S, et al. Induction of gadd45beta by NF-kappaB downregulates pro-apoptotic JNK signalling. Nature 2001;414:308-13
   PubMed Web of Science ®Google Scholar
• Gobert S, Chretien S, Gouilleux F, et al. Identification of tyrosine residues within the intracellular domain of the erythropoietin receptor crucial for STAT5 activation. EMBO J 1996;15:2434-41
   PubMed Web of Science ®Google Scholar
• Socolovsky M, Fallon AE, Wang S, et al. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999;98:181-91
   PubMed Web of Science ®Google Scholar
• Zhang F, Wang S, Cao G, et al. Signal transducers and activators of transcription 5 contributes to erythropoietin-mediated neuroprotection against hippocampal neuronal death after transient global cerebral ischemia. Neurobiol Dis 2007;25:45-53
   PubMed Web of Science ®Google Scholar
• Socolovsky M, Fallon AE, Wang S, et al. Fetal anemia and apoptosis of red cell progenitors in Stat5a-/-5b-/- mice: a direct role for Stat5 in Bcl-X(L) induction. Cell 1999;98:181-91
   PubMed Web of Science ®Google Scholar
• Kretz A, Happold CJ, Marticke JK, et al. Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/AKT pathway activation. Mol Cell Neurosci 2005;29:569-79
   PubMed Web of Science ®Google Scholar
• Dzietko M, Felderhoff-Mueser U, Sifringer M, et al. Erythropoietin protects the developing brain rat Neurobiol Dis 2004;15:177-87
   Google Scholar
• Jacobs-Helber SM, Ryan JJ, Sawyer ST. JNK and p38 are activated by erythropoietin (EPO) but are not induced in apoptosis following EPO withdrawal in EPO-dependent HCD57 cells. Blood 2000;96:933-40
   PubMedGoogle Scholar
• Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol 2007;22:1251-67
   PubMed Web of Science ®Google Scholar
• Feng GS, Shen R, Heng HH, et al. Receptor-binding, tyrosine phosphorylation and chromosome localization of the mouse SH2-containing phosphotyrosine phosphatase Syp. Oncogene 1994;9:1545-50
   PubMedGoogle Scholar
• Klingmuller U, Lorenz U, Cantley LC, et al. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995;80:729-38
   PubMed Web of Science ®Google Scholar
• Wu DW, Stark KC, Dunnington D, et al. SH2-Containing protein tyrosine phosphatase-1 (SHP-1) association with Jak2 in UT-7/Epo cells. Blood Cells Mol Dis 2000;26:15-24
   PubMed Web of Science ®Google Scholar
• Pandey MK, Sung B, Ahn KS, et al. Butein suppresses constitutive and inducible signal transducer and activator of transcription (STAT) 3 activation and STAT3-regulated gene products through the induction of a protein tyrosine phosphatase SHP-1. Mol Pharmacol 2009;75:525-33
   PubMed Web of Science ®Google Scholar
• Maiese K, Li F, Chong ZZ, et al. The Wnt signaling pathway: aging gracefully as a protectionist? Pharmacol Ther 2008;118:58-81
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Maiese K. Targeting WNT, protein kinase B, and mitochondrial membrane integrity to foster cellular survival in the nervous system. Histol Histopathol 2004;19:495-504
   PubMed Web of Science ®Google Scholar
• Chong ZZ, Shang YC, Hou J, et al. Wnt1 neuroprotection translates into improved neurological function during oxidant stress and cerebral ischemia through AKT1 and mitochondrial apoptotic pathways. Oxid Med Cell Longev 2010;3:153-65
   PubMed Web of Science ®Google Scholar
• Tang K, Yang J, Gao X, et al. Wnt-1 promotes neuronal differentiation and inhibits gliogenesis in P19 cells. Biochem Biophys Res Commun 2002;293:167-73
   PubMed Web of Science ®Google Scholar
• Danielyan L, Schafer R, Schulz A, et al. Survival, neuron-like differentiation and functionality of mesenchymal stem cells in neurotoxic environment: the critical role of erythropoietin. Cell Death Differ 2009;16:1599-614
   PubMedGoogle Scholar
• Chong ZZ, Li F, Maiese K. Stress in the brain: novel cellular mechanisms of injury linked to Alzheimer's disease. Brain Res Brain Res Rev 2005;49:1-21
   PubMed Web of Science ®Google Scholar
• Leconte C, Bihel E, Lepelletier FX, et al. Comparison of the effects of erythropoietin and its carbamylated derivative on behaviour and hippocampal neurogenesis in mice. Neuropharmacology 2011;60:354-64
   PubMedGoogle Scholar
• Fan X, Heijnen CJ, van der KM, et al. Beneficial effect of erythropoietin on sensorimotor function and white matter after hypoxia-ischemia in neonatal mice. Pediatr Res 2011;69:56-61
   PubMed Web of Science ®Google Scholar
• Lee ST, Chu K, Park JE, et al. Erythropoietin improves memory function with reducing endothelial dysfunction and amyloid-beta burden in Alzheimer's disease models. J Neurochem 2012;120:115-24
   PubMed Web of Science ®Google Scholar
• Sun ZK, Yang HQ, Pan J, et al. Protective effects of erythropoietin on tau phosphorylation induced by beta-amyloid. J Neurosci Res 2008;86:3018-27
   PubMedGoogle Scholar
• Kook YH, Ka M, Um M. Neuroprotective cytokines repress PUMA induction in the 1-methyl-4-phenylpyridinium (MPP(+)) model of Parkinson's disease. Biochem Biophys Res Commun 2011;411:370-4
   PubMed Web of Science ®Google Scholar
• Kadota T, Shingo T, Yasuhara T, et al. Continuous intraventricular infusion of erythropoietin exerts neuroprotective/rescue effects upon Parkinson's disease model of rats with enhanced neurogenesis. Brain Res 2009;1254:120-7
   PubMed Web of Science ®Google Scholar
• Signore AP, Weng Z, Hastings T, et al. Erythropoietin protects against 6-hydroxydopamine-induced dopaminergic cell death. J Neurochem 2006;96:428-43
   PubMedGoogle Scholar
• Kanaan NM, Collier TJ, Marchionini DM, et al. Exogenous erythropoietin provides neuroprotection of grafted dopamine neurons in a rodent model of Parkinson's disease. Brain Res 2006;1068:221-9
   PubMedGoogle Scholar
• Xue YQ, Zhao LR, Guo WP, et al. Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease. Neuroscience 2007;146:1245-58
   PubMed Web of Science ®Google Scholar
• Xue YQ, Ma BF, Zhao LR, et al. AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease. Gene Ther 2010;17:83-94
   PubMed Web of Science ®Google Scholar
• Rao MS, Hattiangady B, Reddy DS, et al. Hippocampal neurodegeneration, spontaneous seizures, and mossy fiber sprouting in the F344 rat model of temporal lobe epilepsy. J Neurosci Res 2006;83:1088-105
   PubMed Web of Science ®Google Scholar
• Busceti CL, Biagioni F, Aronica E, et al. Induction of the Wnt inhibitor, Dickkopf-1, is associated with neurodegeneration related to temporal lobe epilepsy. Epilepsia 2007;48:694-705
   PubMed Web of Science ®Google Scholar
• Naegele JR. Neuroprotective strategies to avert seizure-induced neurodegeneration in epilepsy. Epilepsia 2007;48(Suppl 2):107-17
   PubMedGoogle Scholar
• Zhu X, Perazella MA. Nonhematologic complications of erythropoietin therapy. Semin Dial 2006;19:279-84
   PubMed Web of Science ®Google Scholar
• Mikati MA, El Hokayem JA, El Sabban ME. Effects of a single dose of erythropoietin on subsequent seizure susceptibility in rats exposed to acute hypoxia at P10. Epilepsia 2007;48:175-81
   PubMed Web of Science ®Google Scholar
• Kondo A, Shingo T, Yasuhara T, et al. Erythropoietin exerts anti-epileptic effects with the suppression of aberrant new cell formation in the dentate gyrus and upregulation of neuropeptide Y in seizure model of rats. Brain Res 2009;1296:127-36
   PubMedGoogle Scholar
• Jung KH, Chu K, Lee ST, et al. Molecular alterations underlying epileptogenesis after prolonged febrile seizure and modulation by erythropoietin. Epilepsia 2011;52:541-50
   PubMed Web of Science ®Google Scholar
• Sozmen SC, Kurul SH, Yis U, et al. Neuroprotective effects of recombinant human erythropoietin in the developing brain of rat after lithium-pilocarpine induced status epilepticus. Brain Dev 2012;34:189-95
   PubMed Web of Science ®Google Scholar
• Bartels C, Spate K, Krampe H, et al. Recombinant Human Erythropoietin: novel Strategies for Neuroprotective/Neuro-regenerative Treatment of Multiple Sclerosis. Ther Adv Neurol Dis 2008;1:193-206
   PubMedGoogle Scholar
• Agnello D, Bigini P, Villa P, et al. Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Res 2002;952:128-34
   PubMed Web of Science ®Google Scholar
• Savino C, Pedotti R, Baggi F, et al. Delayed administration of erythropoietin and its non-erythropoietic derivatives ameliorates chronic murine autoimmune encephalomyelitis. J Neuroimmunol 2006;172:27-37
   PubMed Web of Science ®Google Scholar
• Zhang J, Li Y, Cui Y, et al. Erythropoietin treatment improves neurological functional recovery in EAE mice. Brain Res 2005;1034:34-9
   PubMed Web of Science ®Google Scholar
• Hagemeyer N, Boretius S, Ott C, et al. Erythropoietin attenuates neurological and histological consequences of toxic demyelination in mice. Mol Med 2012;18:628-35
   PubMed Web of Science ®Google Scholar
• Cho YK, Kim G, Park S, et al. Erythropoietin promotes oligodendrogenesis and myelin repair following lysolecithin-induced injury in spinal cord slice culture. Biochem Biophys Res Commun 2012;417:753-9
   PubMed Web of Science ®Google Scholar
• Janik P, Kwiecinski H, Sokolowska B, et al. Erythropoietin concentration in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neural Transm 2010;117:343-7
   PubMed Web of Science ®Google Scholar
• Naganska E, Taraszewska A, Matyja E, et al. Neuroprotective effect of erythropoietin in amyotrophic lateral sclerosis (ALS) model in vitro. Ultrastructural study. Folia Neuropathol 2010;48:35-44
   PubMedGoogle Scholar
• Grunfeld JF, Barhum Y, Blondheim N, et al. Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model. Exp Neurol 2007;204:260-3
   PubMed Web of Science ®Google Scholar
• Koh SH, Kim Y, Kim HY, et al. Recombinant human erythropoietin suppresses symptom onset and progression of G93A-SOD1 mouse model of ALS by preventing motor neuron death and inflammation. Eur J Neurosci 2007;25:1923-30
   PubMed Web of Science ®Google Scholar
• Cao Y. Erythropoietin in cancer: a dilemma in risk therapy. Trends Endocrinol Metab 2012
   PubMedGoogle Scholar
• Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004;305:239-42
   PubMed Web of Science ®Google Scholar
• Erbayraktar S, Grasso G, Sfacteria A, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003;100:6741-6
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang ZG, Gregg SR, et al. The Sonic hedgehog pathway mediates carbamylated erythropoietin-enhanced proliferation and differentiation of adult neural progenitor cells. J Biol Chem 2007;282:32462-70
   PubMed Web of Science ®Google Scholar
• Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci USA 2004;101:14907-12
   PubMed Web of Science ®Google Scholar
• Sturm B, Helminger M, Steinkellner H, et al. Carbamylated erythropoietin increases frataxin independent from the erythropoietin receptor. Eur J Clin Invest 2010;40:561-5
   PubMed Web of Science ®Google Scholar